All In Biotech

Drug Trial Radar · NCT00464438

A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis

Last checked: Nov 20, 2026Latest source record: Sep 21, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 171 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

171

Actual

Start

Jun 2007

Primary completion

Sep 2008

Study completion Sep 2008

Sponsor

Lead sponsor
AllerganAbbVie (ABBV)
Sponsor type
Industry
First posted
Apr 23, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, up to 31 days
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 7 day study to evaluate the safety and efficacy of topical gatifloxacin ophthalmic solution for the treatment of bacterial conjunctivitis in subjects from birth to 31 days of age

Conditions

  • Bacterial Conjunctivitis

Interventions

  • gatifloxacinDrug

    Day 1-6 = 1 drop of study medication three times a day

  • moxifloxacin 0.5% eye dropsDrug

    Day 1-6 = 1 drop of study medication three times a day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Patients With Clearing (Clinical Success) of Conjunctival Erythema and Conjunctival Discharge at Day 7Time frame: Day 7

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Site not named

    Sacramento, California

  • Site not named

    Whitby, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.